Federica Scalorbi
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Correction to: The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro‑entero‑pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu] Lu‑DOTATATE.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 06, 2025
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM).
Journal: Journal of endocrinological investigation
Published: May 19, 2024
Cylindrical TGR as early radiological predictor of RLT progression in GEPNETs: a proof of concept.
Journal: Scientific reports
Published: January 04, 2024
The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE.
Journal: European journal of nuclear medicine and molecular imaging
Published: December 19, 2023
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.
Journal: JAMA network open
Published: February 24, 2022
Update on radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects.
Journal: Tumori
Published: August 18, 2021
Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT.
Journal: Scientific reports
Published: July 05, 2021
Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study.
Journal: Nuclear medicine communications
Published: May 29, 2019
Correction to: Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid.
Journal: Annals of nuclear medicine
Published: May 26, 2018
Last Updated: 09/26/2026